TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29742699

Group type: EXPERIMENTAL
Intervention: Active photobiomodulation in the sublingual region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active photobiomodulation along the spinal cord
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment with photobiomodulation on the skin in the region of the radial artery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photobiomodulation on the skin in the region of the radial artery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham photobiomodulation in the sublingual region
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham photobiomodulation along the spinal cord
Number of subjects: 0
Study: 28421782

Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Milk substitutes (MS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (no analgesic maneuver)
Number of subjects: 144
Study: 25911608

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) protocols
Number of subjects: 220
Study: 24330893

Group type: EXPERIMENTAL
Intervention: Withania somnifera extract (WSE) 500 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21478328

Group type: EXPERIMENTAL
Intervention: Paricalcitol (a selective vitamin D receptor activator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18646364

Group type: EXPERIMENTAL
Intervention: Blue Covarine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothpaste formulations containing Blue Covarine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 15111229

Group type: EXPERIMENTAL
Intervention: Affective priming using unrelated prime-target pairs in a naming task with a short stimulus onset asynchrony (250 ms).
Number of subjects: 0
Study: 10417584

Group type: EXPERIMENTAL
Intervention: Combined CO2/Er:YAG laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: CO2 laser alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 20
Study: 7589376

Group type: EXPERIMENTAL
Intervention: Nebulized L-ASA (90 mg.ml-1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched placebo (glycine solution, 30 mg.ml-1)
Number of subjects: 9
Study: 2239115

Group type: EXPERIMENTAL
Intervention: Intermittent high frequency ventilation (IHFV) at 160 b.p.m.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intermittent high frequency ventilation (IHFV) at 60 b.p.m.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intermittent high frequency ventilation (IHFV) with constant Paco2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal ventilation and high frequency ventilation (HFV)
Number of subjects: 10
Study: 7365058

Group type: EXPERIMENTAL
Intervention: Family self-control instruction (experimental group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Follow-up assessments (2, 6, and 12 months)
Number of subjects: 33
Study: 31125276

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 95
Study: 29065020

Group type: EXPERIMENTAL
Intervention: Personalized Feedback (PF) video
Number of subjects: 21

Group type: COMPARATOR
Intervention: Scheduled repeated practice (21 trainees)
Number of subjects: 21
Study: 26920359

Group type: EXPERIMENTAL
Intervention: eGFR <60 mL/min/1.73 m(2) and UACR ≥30 mg/g
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: UACR ≥30 mg/g
Number of subjects: 665

Group type: COMPARATOR
Intervention: Neither marker of CKD (eGFR ≥60 mL/min/1.73 m(2) and UACR <30 mg/g)
Number of subjects: 665
Study: 25935942

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tamsulosin non-users
Number of subjects: 200
Study: 21700602

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19318523

Group type: EXPERIMENTAL
Intervention: Handwashing intervention program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 17626026

Group type: COMPARATOR
Intervention: One AEC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two AECs
Number of subjects: 60
Study: 14734673

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-P
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-C
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in PD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-P and MSA-C
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-P and PD
Number of subjects: 49
Study: 11124917

Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional Ventilation (CMV)
Number of subjects: 142
Study: 9671427

Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride 0.50% (Betoptic) administered to 15 POAG and 7 NTG eyes
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride 0.25% (Betoptic S) administered to 17 POAG and 9 NTG eyes
Number of subjects: 48
Study: 8024354

Group type: EXPERIMENTAL
Intervention: Nutropin (0.2 mg/kg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Protropin (0.2 mg/kg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2925041

Group type: EXPERIMENTAL
Intervention: Intravenous phenylalanine before treatment with carbidopa
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbidopa treatment
Number of subjects: 12
Study: 31722694

Group type: EXPERIMENTAL
Intervention: Structured lifestyle education programme (STEPWISE)
Number of subjects: 51
Study: 29759616

Group type: EXPERIMENTAL
Intervention: CFAE ablation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CEA ablation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CFAE or CEA ablation
Number of subjects: 66
Study: 25968599

Group type: COMPARATOR
Intervention: Multi-component intervention programme targeting school and family environment, including healthy diet and physical activity promotion, activities to increase physical activity, participation in the 'Villa Vitality' programme, healthy cooking skills workshops, and provision of information to families.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual practice (control group).
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Multi-component intervention programme targeting school and family environment.
Number of subjects: 1000
Study: 24035099

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.2 mg, orally, Study 1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (22 mg, intravenously, Study 2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control group for both studies)
Number of subjects: 32
Study: 21900646

Group type: EXPERIMENTAL
Intervention: Closed-loop dynamic cardiac baroreflex sensitivity (sequence technique)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Closed-loop low-frequency baroreflex transfer function gain
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Open-loop low-frequency transfer function gain (white-noise stimulation)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximal gain of carotid-cardiac baroreflex stimulus-response curve
Number of subjects: 10
Study: 19443532

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study: 17680911

Group type: EXPERIMENTAL
Intervention: omalizumab + SIT-grass
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: omalizumab + SIT-birch
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo + SIT-grass
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo + SIT-birch
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 1 year after treatment (all groups)
Number of subjects: 92
Study: 14981776

Group type: EXPERIMENTAL
Intervention: Rhinovirus RNA
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Enterovirus RNA
Number of subjects: 161

Group type: COMPARATOR
Intervention: Asymptomatic control children
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: PCR-positive children
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Overall persistence of viral RNA
Number of subjects: 161
Study: 11752106

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg subcutaneous methylnaltrexone plus morphine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg subcutaneous methylnaltrexone plus morphine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine (0.05 mg/kg intravenously)
Number of subjects: 12
Study: 9695655

Group type: EXPERIMENTAL
Intervention: Alpha-L-fucosidase (ALF) activity in patients with recurrent cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AST activity in patients with recurrent cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AST activity in patients with ductal and/or bladder cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ALT activity in patients with recurrent cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ALT activity in patients with ductal and/or bladder cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GGT activity in patients with recurrent cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GGT activity in patients with ductal and/or bladder cholelithiasis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GGT activity in patients with focal changes in the liver
Number of subjects: 36
Study: 8033514

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (240 kJ/h)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 21
Study: 2558404

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-fractioned heparin (NFH)
Number of subjects: 10
Study: 4142795

Group type: EXPERIMENTAL
Intervention: Bleomycin 150 mg followed by radiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 20
Study: 31375279

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy at 66.6Gy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Radical prostatectomy alone (observation group)
Number of subjects: 250
Study: 28302407

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H7N1 vaccine (3.75μg or 7.5μg hemagglutinin with AS03A or AS03B)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H7N1 vaccine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 360
Study: 26180217

Group type: EXPERIMENTAL
Intervention: Referral to a free, proactive quitline
Number of subjects: 112
Study: 23075913

Group type: EXPERIMENTAL
Intervention: Mogen clamp
Number of subjects: 640

Group type: COMPARATOR
Intervention: Gomco
Number of subjects: 640

Group type: COMPARATOR
Intervention: Plastibell
Number of subjects: 640
Study: 21562746

Group type: EXPERIMENTAL
Intervention: 50 mg ZnSO(4) daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18457756

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for pre- and interconceptional women
Number of subjects: 692
Study: 17084137

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) delivered by general practitioners (GPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 14717683

Group type: EXPERIMENTAL
Intervention: Clinical practice guideline (CPG) provided to the intervention group after pre-test assessment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CPG provided).
Number of subjects: 0
Study: 11335734

Group type: EXPERIMENTAL
Intervention: 10 microg at 0 and 4 or 0 and 6 months
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: 5 microg at 0 and 6 or 0, 2, and 4 or 0, 1, and 6 months
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: One 10-microg dose
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: One 5-microg dose
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Two or three 5-microg doses
Number of subjects: 1026

Group type: COMPARATOR
Intervention: 2-dose regimen of Recombivax HB
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Two 10-microg doses
Number of subjects: 1026
Study: 9453874

Group type: EXPERIMENTAL
Intervention: Minimally invasive laparoscopic tubal ligation under sedation and local anesthesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional laparoscopic tubal ligation under general anesthesia
Number of subjects: 14
Study: 8392285

Group type: EXPERIMENTAL
Intervention: AZQ at 15 mg/day for 3 days i.v. every 4 weeks
Number of subjects: 249

Group type: COMPARATOR
Intervention: BCNU at 200 mg i.v. every 8 weeks
Number of subjects: 249
Study: 3521859

Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (50 mg BID)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Octylonium bromide (20 mg TID)
Number of subjects: 40
Study: 29610401

Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine
Number of subjects: 219
Study: 27834742

Group type: EXPERIMENTAL
Intervention: Hypothermia plus antishivering treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 120
Study: 24105103

Group type: EXPERIMENTAL
Intervention: Irbesartan 300/12.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Irbesartan 300/25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 300/12.5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 300/25 mg
Number of subjects: 30
Study: 22664783

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once-daily
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted according to Japanese guidelines)
Number of subjects: 1280
Study: 20832925

Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100 mg caffeine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 200 mg caffeine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 mg caffeine
Number of subjects: 36
Study: 18395480

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.012 mg/kg/day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Individualized dosing (ID) GH regimen
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fixed dosing (FD) GH regimen (0.012 mg/kg/day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fixed dosing (FD) GH regimen
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 57
Study: 15737659

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 14649535

Group type: EXPERIMENTAL
Intervention: Group education before cardiac catheterization
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no education intervention)
Number of subjects: 62
Study: 11118463

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 75 mg/m² and Cisplatin (CDDP) 100 mg/m² for six cycles at 3-week intervals; 232 (81%) received all six cycles.
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) and Cisplatin (CDDP) regimen with RDI less than 0.6.
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) and Cisplatin (CDDP) regimen.
Number of subjects: 287
Study: 9104519

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl plus im ketorolac (Group A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: im ketorolac alone (Group P)
Number of subjects: 92
Study: 8251720

Group type: EXPERIMENTAL
Intervention: Photosensitized Oxidation Auto‐Hemotherapy (POAH) with Buyang Huanwu Tang therapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Photosensitized Oxidation Auto‐Hemotherapy (POAH) only
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 115
Study: 3513515

Group type: EXPERIMENTAL
Intervention: 240 mg verapamil daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29298664

Group type: EXPERIMENTAL
Intervention: Auto-titrating continuous positive airway pressure (APAP) applied during sleep for 72 hours after surgery or until discharge if discharged before 72 hours.
Number of subjects: 634

Group type: COMPARATOR
Intervention: Control group - routine care, no APAP.
Number of subjects: 634
Study: 27809810

Group type: EXPERIMENTAL
Intervention: Directly mailed a second reminder including a HPV self-sampling kit
Number of subjects: 9327

Group type: EXPERIMENTAL
Intervention: Mailed a second reminder offering a HPV self-sampling kit, to be ordered by e-mail, text message, phone, or through a webpage
Number of subjects: 9327

Group type: COMPARATOR
Intervention: Mailed a second reminder for a practitioner-collected sample
Number of subjects: 9327

Group type: EXPERIMENTAL
Intervention: HPV self-collected sample
Number of subjects: 9327
Study: 25411033

Group type: EXPERIMENTAL
Intervention: Blended lentils (B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole lentils (W)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: α-galactosidase
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study: 23184118

Group type: EXPERIMENTAL
Intervention: Gastrografin (3 mL/kg diluted 1:3 with water)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20484941

Group type: EXPERIMENTAL
Intervention: Diet plus WBV (VIBRATION)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diet only (DIET)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Diet plus fitness (FITNESS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (CONTROL)
Number of subjects: 79
Study: 18410889

Group type: EXPERIMENTAL
Intervention: Resting energy expenditure (REE) in children and adolescents on hemodialysis
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adjusted resting energy expenditure (REE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Total energy expenditure (TEE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nutritional status and growth deficit evaluation
Number of subjects: 25
Study: 16821209

Group type: EXPERIMENTAL
Intervention: DHEA therapy (150 mg oral DHEA daily for 40 days)
Number of subjects: 30
Study: 14581438

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (90 mg) administered intravenously every 3 weeks for 27 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered every 3 weeks for 27 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9826207

Group type: EXPERIMENTAL
Intervention: Pancreas-kidney transplantation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nondiabetic kidney transplantation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 31
Study: 8728804

Group type: EXPERIMENTAL
Intervention: Psychological preparation (psychoprophylaxis)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no psychological preparation)
Number of subjects: 60
Study: 3137888

Group type: EXPERIMENTAL
Intervention: Tegafur 400 mg/m2 and Tamoxifen 20 mg/daily (Group B)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Tegafur 400 mg/m2 alone (Group A)
Number of subjects: 554
Study: 28741175

Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management (GAM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 28716108

Group type: EXPERIMENTAL
Intervention: Esoteric Connective Tissue Therapy (ECTT), 40 minutes per session, 4 weekly treatments
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physiotherapy, 50 minutes per session, 4 weekly treatments
Number of subjects: 100
Study: 25703777

Group type: EXPERIMENTAL
Intervention: Assisting Hand Assessment (AHA) and Jebsen‐Taylor Test of Hand Function (JTTHF) dominant upper limb score
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TVPS‐3 Visual Sequential Memory, TVPS‐3 Visual Closure, and JTTHF dominant upper limb score
Number of subjects: 101
Study: 23811627

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 80
Study: 21696071

Group type: EXPERIMENTAL
Intervention: Lower uterine segment compression (LUSC) for 10 minutes
Number of subjects: 686

Group type: COMPARATOR
Intervention: Control group (standard care with oxytocin, clamping and cutting umbilical cords, controlled cord traction, and uterine massage)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Lower uterine segment compression (LUSC)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 686
Study: 19349308

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Supportive stress management
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study: 17132270

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (400 IU RRR-alpha-tocopherol/day for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15595704

Group type: EXPERIMENTAL
Intervention: Grafted bone (iliac crest) used as onlay blocks, maxillary sinus inlay blocks, or in particulate form
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nongrafted bone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Block grafts after 6 months
Number of subjects: 40
Study: 11841196

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 5 mg/d
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 10 mg/d
Number of subjects: 57

Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA) 1.6 g/d
Number of subjects: 57
Study: 9150322

Group type: EXPERIMENTAL
Intervention: Budesonide (100 microg per nasal cavity b.i.d.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42